title: Elevated B cell-activating factor of the tumour necrosis factor family in coeliac disease.
abstract: OBJECTIVE
  The B cell-activating factor of the tumour necrosis factor (TNF) family (BAFF) was recently described as a critical survival factor for B cells, and its expression is increased in several autoimmune diseases. Abnormal production of BAFF disturbs immune tolerance allowing the survival of autoreactive B cells and participates in the progression of B-cell lymphomas. Coeliac disease (CD) is a common autoimmune disorder induced by gluten intake in genetically predisposed individuals, associated with autoantibody production and with an increased risk of lymphoma at follow-up. The purpose of this study was to investigate the possible implications of BAFF in CD.
  
  
  METHODS
  Seventy-three patients with small-bowel biopsies and laboratory-proven diagnosis of CD were included in the study. All serum samples were analysed before the start of a gluten-free diet (GFD). In 12 cases, one or more samples were analysed during follow-up of the GFD. Seventy-seven blood donors were taken as controls. Serum BAFF levels and anti-transglutaminase (a-tTG) antibodies were assessed by ELISA and endomysial antibodies by indirect immunofluorescence.
  
  
  RESULTS
  Serum BAFF levels appeared to be significantly more elevated in CD patients than in controls (p<0.0001) and, compared with other autoimmune diseases where BAFF is increased, a much larger percentage (80.8%) of CD patients presented BAFF levels above the normal range. In addition, serum BAFF levels were found to correlate with a-tTG antibody levels (p =0.0007) and there was a significant reduction of BAFF after introduction of a GFD.
  
  
  CONCLUSIONS
  BAFF may represent a possible pathogenic factor in CD. Its implications for the diagnosis, prognosis and treatment of CD should also be assessed.
authors.affiliation: Clinic of Rheumatology, DPMSC, University of Udine, Udine, Italy. martina.fabris@uniud.it
authors.forename: Martina
authors.initials: M
authors.lastname: Fabris
authors.forename: Daniela
authors.initials: D
authors.lastname: Visentini
authors.forename: Valli
authors.initials: V
authors.lastname: De Re
authors.forename: Alessia
authors.initials: A
authors.lastname: Picierno
authors.forename: Roberto
authors.initials: R
authors.lastname: Maieron
authors.forename: Renato
authors.initials: R
authors.lastname: Cannizzaro
authors.forename: Danilo
authors.initials: D
authors.lastname: Villalta
authors.forename: Francesco
authors.initials: F
authors.lastname: Curcio
authors.forename: Salvatore
authors.initials: S
authors.lastname: De Vita
authors.forename: Elio
authors.initials: E
authors.lastname: Tonutti
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001323:Autoantibodies / Q000097:blood; D053264:B-Cell Activating Factor / Q000097:blood*; D002446:Celiac Disease / Q000097:blood*; D002648:Child; D002675:Child, Preschool; D018450:Disease Progression; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D019084:Fluorescent Antibody Technique, Indirect; D006801:Humans; D007223:Infant; D008297:Male; D008875:Middle Aged; D018709:Statistics, Nonparametric
chemical_list: D001323:Autoantibodies; D053264:B-Cell Activating Factor